表纸
市场调查报告书

抗微生物药抗性 (AMR) 诊断市场、策略、趋势

Antimicrobial Resistance Diagnostics Market, Strategies & Trends by Pathogen and Technology with Executive Guides and Customization 2020 to 2024

出版商 Howe Sound Research 商品编码 654772
出版日期 内容资讯 英文 214 Pages
商品交期: 最快1-2个工作天内
价格
Back to Top
抗微生物药抗性 (AMR) 诊断市场、策略、趋势 Antimicrobial Resistance Diagnostics Market, Strategies & Trends by Pathogen and Technology with Executive Guides and Customization 2020 to 2024
出版日期: 2019年11月01日内容资讯: 英文 214 Pages
简介

本报告以全球抗微生物药抗性 (AMR) 诊断市场为研究主题,提供6个主要的病原菌的机会确认,发展的市场预测提供,20家主要企业的简介汇整。

第1章 简介、市场定义

第2章 动态市场概要

  • 市场参与企业:作用及影响
  • 抗微生物药抗性 (AMR)的理解
  • 新的抗生素 & 技术的路程的变化
  • 抗微生物药抗性 (AMR) 的诊断主要的作用

第3章 AMR的市场机会

  • AMR的大规模的市场机会
  • 诊断技术发展的机会
  • 抗生素抗性的近几年的发展

第4章 主要生物科技企业和其技术

  • 诊断

第5章 全球市场

  • 全球市场:各国

第6章 全球市场:各病原菌

  • 全球市场:各病原菌
  • DRSP
  • DRC
  • CD
  • MRSA
  • DRNG
  • DRNTS

第7章 AMR诊断:各技术

  • 全球市场:各技术
  • 细菌培养
  • 免疫检测
  • PCR (聚合酵素链锁反应)
  • 遗传基因筛检
  • 质谱仪
  • 迅速检验,POC,其他

第8章 AMR诊断的未来展望

本网页内容可能与最新版本有所差异。详细情况请与我们联系。

目录

OVERVIEW:

Diagnostics are leading the charge in reducing the threat posed by antimicrobial resistance. New diagnostic technologies, beyond gene sequencing, are under development to capture this growing market. We have looked at the technology picture, giving you plain language understanding of the different ways pathogens, and infections, can be diagnosed. We have identified the 6 Key Large Pathogen Opportunities in this space and developed market forecasts. We profile 20 companies, large and small, working in this area.

Our research makes you the expert in your organization. Get our research team working for you by ordering all, or a portion, of this comprehensive report. Your credit card order sends the report to your inbox instantly. Check all your licensing options but don't worry, your order is available as a credit if you wish to upgrade to more information. We wrote this report and we are ready, by phone or email, to help you use it. As always, assistance, and additional specific data, is provided without additional charges.

All report data is available in Excel format on request.

Make investment decisions and valuations with confidence using the latest data.

ABOUT THE LEAD AUTHOR:

Mr. Greg Powell, B.SC., M.B.A is the President of Howe Sound Research. He is an experienced business and clinical professional. He is co-author of the paper "The Radioimmunoassay of Angiotensinogen by Antibody Trapping." He has worked in laboratory testing and management for over 20 years. Mr. Powell's education includes:

  • B.Sc. (Chemistry) University of BC
  • M.B.A. (Finance and Policy) University of BC
  • Market Research Seminar - Burke Institute
  • Finance for Senior Executives - Harvard Business School

Table of Contents

i. Antimicrobial Resistance - Strategic Situation Analysis

ii. Guide for Executives, Marketing, Sales and Business Development Staff

iii. Guide for Management Consultants and Investment Advisors

1. Introduction and Market Definition

  • 1.1 The Growing Threat and Opportunity of Antimicrobial Resistance
  • 1.2 Defining the Opportunity
    • 1.2.1 Revenue Market Size
  • 1.3 Methods and Sources
    • 1.3.1 Authors
    • 1.3.2 Sources
  • 1.4 U.S. Antibiotic Markets - Perspective
    • 1.4.1 U.S. Outpatient Use of Antibiotics
    • 1.4.2 U.S. Pharmaceutical Spending

2. Overview of a Dynamic Market

  • 2.1 Market Players - Roles & Impacts
    • 2.1.1 Drug manufacturers - Larger/pharmaceutical
    • 2.1.2 Drug manufacturers - Generic
    • 2.1.3 Contract Research and Manufacturing
    • 2.1.4 In Vitro Diagnostics Industry
    • 2.1.5 Drug Marketing Companies
    • 2.1.6 Biotechnology Companies
    • 2.1.7 Regulatory Bodies
  • 2.2 Understanding Antimicrobial Resistance
    • 2.2.1 What is Antimicrobial Resistance (AMR)
    • 2.2.2 Bacteria and Other Microbes
    • 2.2.3 The History of Antibiotics
    • 2.2.4 The Role of Animal Husbandry
    • 2.2.5 The Implications of Horizontal Transfer
    • 2.2.6 The Threat of AMR
  • 2.3 The Changing Road to New Antibiotics & Technologies
  • 2.4 The Key Role of Diagnostics in AMR

3. The Market Opportunity of AMR

  • 3.1 The Key Large Market Opportunities in AMR
    • 3.1.1 Streptococcus Pneumoniae (DRSP)
    • 3.1.2 Campylobacter (DRC)
    • 3.1.3 Clostridium Difficile (CD)
    • 3.1.4 Staphylococcus aureus (MRSA)
    • 3.1.5 Neisseria gonorrhoeae (DRNG)
    • 3.1.6 Salmonella (DRNTS)
  • 3.2 Diagnostic Technology Development Opportunities
    • 3.2.1 What's Wrong with Microbiology
    • 3.2.2 The Features Battleground of Infectious Disease Diagnostics
    • 3.2.3 Multiplex vs. POC/Rapid
    • 3.2.4 The Miracle of Genetics
    • 3.2.5 From Multiple Pathogens to All Pathogens - The Next Next Generation
    • 3.2.6 Gene Sequence Diagnostics WITHOUT the Sequencing.
    • 3.2.7 Markers of Resistance.
    • 3.2.8 What Happens to the Microbiology Lab?
  • 3.4. Antibiotic Resistance Recent Developments
    • Importance of These Developments
    • How to Use This Section
    • New method to test for infection resistance.
    • Qiagen launches AMR database
    • Antibiotic resistance test for gonorrhea gets FDA breakthrough
    • Qiagen, Ares Genetics Ink Licensing Pact for AMR Bioinformatics
    • OpGen to File First 510(k) for AMR Gene Panel
    • Curetis' Subsidiary Ares Genetics Teams Up with Sandoz in Fight Against AMR
    • GeneCapture to determine antibiotic sensitivity in an automated rapid portable device
    • Quick identification of multidrug-resistant pathogens
    • OpGen to Offer Qiagen Nucleic Acid Purification Tech With Acuitas Pathogen Panel
    • Metagenomics Enables Researchers to Uncover Drug Resistance Genes
    • Rapid detection of multi-drug-resistant bacteria
    • Improved Diagnostics Fail to Halt the Rise of Tuberculosis
    • High Throughput Manufacturing Lines to Answer Growing Needs for Diagnosis Cartridges
    • New solution for diagnosing antibiotic-resistant bacteria
    • MALDI-TOF - Results in Minutes not Days
    • CRISPR Tool Used to Uncover Infections
    • Automated Blood Tests Startup MeMed Raises Funds, Wins Grant
    • BD, Check-Points Receive CE Mark for Resistant Organism Screening Test
    • LiDia® BSI Detects Pathogens and Antimicrobial Resistance
    • New tool can Track Resistant Malaria
    • Rapid Test Developed to Measure Antibiotic Resistance in Patients with UTIs
    • Longitude Funds for POC Tests
    • New test can identify dangerous bacteria with resistance to last-resort antibiotic bioMérieux receives FDA clearance for expanded pathogen identification capability
    • OpGen Inks Deal to Use Thermo Fisher PCR Tech in Acuitas Gene Panel Tests
    • Hospital Plumbing Harbors Antibiotic Resistant Bacteria
    • Acquisition Strategy Fills Out Roche's Diagnostic Pipeline
    • Curetis Gets Singapore Approval for Pneumonia Test
    • PlexBio, Denka to Codevelop Sepsis, Multidrug Resistance MDx
    • Curetis, MGI Collaborate to Combine Sample Prep, NGS Technologies

4. Key Biotechnology Companies and Their Technology

  • 4.1 Diagnostics
    • 4.1.1 1928 Diagnostics
    • 4.1.2 Sense Biodetection.
    • 4.1.3 Fusion Genomics.
    • 4.1.4 Day Zero Diagnostics
    • 4.1.5 Inflammatix
    • 4.1.6 Hutman Diagnostics
    • 4.1.8 bioMérieux Diagnostics
    • 4.1.9 Curetis N.V. / Curetis GmbH
    • 4.1.10 Great Basin Corporation
    • 4.1.11 Becton, Dickinson and Company
    • 4.1.12 Roche Diagnostics
    • 4.1.13 Cepheid (now Danaher)
    • 4.1.14 Atlas Genetics
    • 4.1.14 Accelerate Diagnostics
    • 4.1.15 Seimens
    • 4.1.16 Abbott Diagnostics
    • 4.1.17 Thermo Fisher
    • 4.1.18 Bio - Rad
    • 4.1.19 GenePOC Diagnostics
    • 4.1.20 Sysmex
    • 4.1.21 Ortho Clinical

5. The Global Market

  • 5.1 Global Market by Country

6. Global Market by Pathogens

  • 6.1 Global Market by Pathogens
  • 6.2 DRSP
  • 6.3 DRC
  • 6.4 CD
  • 6.5 MRSA
  • 6.5 DRNG
  • 6.6 DRNTS

7. AMR Diagnostics by Technology

  • 7.1 Global Market by Technology
  • 7.2 Bacterial Culture
  • 7.3 Immunoassay
  • 7.4 Polymerase Chain Reaction
  • 7.5 Genetic Sequencing
  • 7.6 Mass Spectrometer
  • 7.7 Rapid, POC and Other

8. Vision of the Future of AMR Diagnostics

Table of Tables

  • Table 1 USA - Outpatient Use of Antibiotics by Class
  • Table 2 USA - Outpatient Use of Antibiotics Top 5
  • Table 3 Market Players by Type
  • Table 4 Known Human Pathogenic Diseases
  • Table 5 The Key Market Opportunities
  • Table 6 - Market Potential DRSP Diagnostic
  • Table 7 - Market Potential DRC Diagnostic
  • Table 8 - Market Potential CD Diagnostic
  • Table 9 - Market Potential CD Diagnostic
  • Table 10 Market Potential DRNG Diagnostic
  • Table 11 Market Potential DRNTS Diagnostic
  • Table 12 - Key AMR Diagnostics Issues
  • Table 13 The Global AMR Diagnostic Market by Country
  • Table 14 Global Market by Pathogen
  • Table 15 DRSP Diagnostics by Country
  • Table 16 DRC Diagnostics by Country
  • Table 17 CD Diagnostics by Country
  • Table 18 MRSA Diagnostics by Country
  • Table 19 DRNG Diagnostics by Country
  • Table 20 DRNTS Diagnostics by Country
  • Table 21 Global Market by Technology
  • Table 22 Culture Diagnostics by Country
  • Table 23 Immunoassay Diagnostics by Country
  • Table 24 PCR Diagnostics by Country
  • Table 25 NGS Diagnostics by Country
  • Table 26 MS Diagnostics by Country
  • Table 27 Rapid, POC and Other Diagnostics by Country

Table of Figures

  • Figure 1 Pharmaceutical Spending History by Country
  • Figure 2 AMR and Antibiotic Introduction
  • Figure 3 The Death Toll of AMR
  • Figure 4 AMR Diagnostics - Key Countries
  • Figure 5 Chart of Share Change by Pathogen
  • Figure 6 Pathogen Share by Year
  • Figure 7 Pathogen Segment Growth Rates
  • Figure 8 Chart - DRSP Segment vs Total Market
  • Figure 9 Chart - DRC Segment vs Total Market
  • Figure 10 Chart - CD segment vs Total Market
  • Figure 11 Chart - MRSA Segment vs Total Market
  • Figure 12 Chart - DRNG Segment vs Total Market
  • Figure 13 Chart - DRNTS Segment vs Total Market
  • Figure 14 Chart of Growth by Technology
  • Figure 15 Chart - Technology Change in Planning Period
  • Figure 16 Chart - Technology Share by Year
  • Figure 17 Chart - Bacterial Culture vs Total Market
  • Figure 18 Chart - Immunoassay vs Total Market
  • Figure 19 Chart - PCR vs Total Market
  • Figure 20 Chart - NGS vs Total Market
  • Figure 21 Chart - Mass Spectrometry vs Total Market
  • Figure 22 Chart - Rapid POC vs Total Market
Back to Top